FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157354264> ?p ?o ?g. }

• W2157354264 endingPage "1225" @default.
• W2157354264 startingPage "1216" @default.
• W2157354264 abstract "New therapeutic options are needed for patients with heavily pretreated breast cancer. Etirinotecan pegol is a long-acting topoisomerase-I inhibitor designed to provide prolonged tumour-cell exposure to SN38, the active metabolite. We aimed to assess the efficacy and safety of two etirinotecan pegol dosing schedules in patients with previously treated metastatic breast cancer to determine an optimum dosing schedule for phase 3 trials.In this randomised, two-stage, open-label phase 2 trial, we recruited patients aged 18 years or older who had received taxane therapy and undergone two or fewer previous chemotherapy regimens for metastatic breast cancer, with an Eastern Cooperative Oncology Group performance status of 0 or 1, from 18 sites in three countries. Eligible patients were randomly assigned (1:1) to etirinotecan pegol 145 mg/m(2) every 14 days or every 21 days. The primary endpoint was the proportion of patients with a confirmed objective response as defined by Response Evaluation Criteria in Solid Tumors version 1.0, analysed by intention to treat. Safety was assessed in all patients who received at least one dose of study drug.70 patients (35 in each group) were randomly assigned to treatment between Feb 17, 2009 and April 13, 2010. Of the 70 patients, 20 (29%; 95% CI 18·4-40·6) achieved an objective response (two [3%] had a complete response and 18 [26%] had a partial response). Ten patients on the 14-day schedule achieved an objective response (29%; 95% CI 14·6-46·3; eight partial responses, two complete responses) as did ten on the 21-day schedule (29%; 95% CI 14·6-46·3; all partial responses). The most common grade 3 or worse adverse events were delayed diarrhoea (seven [20%] of 35 patients on the 14-day schedule vs eight [23%] of 35 patients on the 21-day schedule), fatigue (five [14%] vs three [9%]), neutropenia (four [11%] vs four [11%]), and dehydration (three [9%] vs four [11%]); 14 [20%] patients discontinued treatment because of drug-related toxicity. There were two possible drug-related deaths (acute renal failure and septic shock) in the 14-day group; other drug-related serious adverse events reported by more than one patient included ten [14%] patients with diarrhoea (six [17%] patients on the 14-day schedule vs four [11%] on the 21-day schedule), six [9%] with dehydration (two [6%] vs four [11%]), two [3%] with nausea (two [6%] vs none), and two [3%] with vomiting (two [6%] vs none).On the basis of the overall clinical data, pharmacokinetics, and tolerability profile, etirinotecan pegol 145 mg/m(2) every 21 days has been selected for a phase 3 trial against treatment of physician's choice in patients with advanced breast cancer." @default.
• W2157354264 created "2016-06-24" @default.
• W2157354264 creator A5003969811 @default.
• W2157354264 creator A5010064853 @default.
• W2157354264 creator A5032926801 @default.
• W2157354264 creator A5037359057 @default.
• W2157354264 creator A5045668242 @default.
• W2157354264 creator A5048383667 @default.
• W2157354264 creator A5051516231 @default.
• W2157354264 creator A5051980635 @default.
• W2157354264 creator A5052831034 @default.
• W2157354264 creator A5055804087 @default.
• W2157354264 creator A5057190300 @default.
• W2157354264 creator A5065306642 @default.
• W2157354264 creator A5071585351 @default.
• W2157354264 creator A5071675004 @default.
• W2157354264 creator A5081726695 @default.
• W2157354264 creator A5085330947 @default.
• W2157354264 creator A5089364285 @default.
• W2157354264 creator A5090950052 @default.
• W2157354264 date "2013-11-01" @default.
• W2157354264 modified "2023-10-12" @default.
• W2157354264 title "Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study" @default.
• W2157354264 cites W1965966073 @default.
• W2157354264 cites W1971284713 @default.
• W2157354264 cites W2015294539 @default.
• W2157354264 cites W2026142028 @default.
• W2157354264 cites W2059452466 @default.
• W2157354264 cites W2074890479 @default.
• W2157354264 cites W2075411370 @default.
• W2157354264 cites W2095832858 @default.
• W2157354264 cites W2103979740 @default.
• W2157354264 cites W2109800555 @default.
• W2157354264 cites W2119974083 @default.
• W2157354264 cites W2121917721 @default.
• W2157354264 cites W2127152525 @default.
• W2157354264 cites W2139248078 @default.
• W2157354264 cites W2140837341 @default.
• W2157354264 cites W2147081651 @default.
• W2157354264 cites W2147094816 @default.
• W2157354264 cites W2154908899 @default.
• W2157354264 cites W2158891743 @default.
• W2157354264 cites W2318457062 @default.
• W2157354264 cites W2464833389 @default.
• W2157354264 cites W2092998911 @default.
• W2157354264 doi "https://doi.org/10.1016/s1470-2045(13)70429-7" @default.
• W2157354264 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24095299" @default.
• W2157354264 hasPublicationYear "2013" @default.
• W2157354264 type Work @default.
• W2157354264 sameAs 2157354264 @default.
• W2157354264 citedByCount "65" @default.
• W2157354264 countsByYear W21573542642013 @default.
• W2157354264 countsByYear W21573542642014 @default.
• W2157354264 countsByYear W21573542642015 @default.
• W2157354264 countsByYear W21573542642016 @default.
• W2157354264 countsByYear W21573542642017 @default.
• W2157354264 countsByYear W21573542642018 @default.
• W2157354264 countsByYear W21573542642019 @default.
• W2157354264 countsByYear W21573542642020 @default.
• W2157354264 countsByYear W21573542642021 @default.
• W2157354264 countsByYear W21573542642022 @default.
• W2157354264 countsByYear W21573542642023 @default.
• W2157354264 crossrefType "journal-article" @default.
• W2157354264 hasAuthorship W2157354264A5003969811 @default.
• W2157354264 hasAuthorship W2157354264A5010064853 @default.
• W2157354264 hasAuthorship W2157354264A5032926801 @default.
• W2157354264 hasAuthorship W2157354264A5037359057 @default.
• W2157354264 hasAuthorship W2157354264A5045668242 @default.
• W2157354264 hasAuthorship W2157354264A5048383667 @default.
• W2157354264 hasAuthorship W2157354264A5051516231 @default.
• W2157354264 hasAuthorship W2157354264A5051980635 @default.
• W2157354264 hasAuthorship W2157354264A5052831034 @default.
• W2157354264 hasAuthorship W2157354264A5055804087 @default.
• W2157354264 hasAuthorship W2157354264A5057190300 @default.
• W2157354264 hasAuthorship W2157354264A5065306642 @default.
• W2157354264 hasAuthorship W2157354264A5071585351 @default.
• W2157354264 hasAuthorship W2157354264A5071675004 @default.
• W2157354264 hasAuthorship W2157354264A5081726695 @default.
• W2157354264 hasAuthorship W2157354264A5085330947 @default.
• W2157354264 hasAuthorship W2157354264A5089364285 @default.
• W2157354264 hasAuthorship W2157354264A5090950052 @default.
• W2157354264 hasBestOaLocation W21573542642 @default.
• W2157354264 hasConcept C121608353 @default.
• W2157354264 hasConcept C126322002 @default.
• W2157354264 hasConcept C143998085 @default.
• W2157354264 hasConcept C203092338 @default.
• W2157354264 hasConcept C2775930923 @default.
• W2157354264 hasConcept C2777288759 @default.
• W2157354264 hasConcept C2777511904 @default.
• W2157354264 hasConcept C2779984678 @default.
• W2157354264 hasConcept C31760486 @default.
• W2157354264 hasConcept C530470458 @default.
• W2157354264 hasConcept C535046627 @default.
• W2157354264 hasConcept C71924100 @default.
• W2157354264 hasConceptScore W2157354264C121608353 @default.
• W2157354264 hasConceptScore W2157354264C126322002 @default.
• W2157354264 hasConceptScore W2157354264C143998085 @default.
• W2157354264 hasConceptScore W2157354264C203092338 @default.

• next